Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Cladribine plus HAG for relapsed/refractory AML (CHAG)
ChiCTR2300069328Phase 4Not yet recruiting
- Sponsor
- Southwest Hospital of Army Medical University
- Start
- Dec 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of cladribine in acute myeloid leukemia (AML), sponsored by Southwest Hospital of Army Medical University. Primary endpoint: Complete response rate (CR + CRi). Planned start Dec 2022; status: not yet recruiting.
02
Drugs
cladribine
03
Conditions
acute myeloid leukemia (AML)
Beyond the preview
Go deeper on ChiCTR2300069328.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2300069328.